Prof. Dr. Loibl is Chief Executive Officer of the GBG Forschungs GmbH and Chair of the German Breast Group (study group).

Prof. Dr. Sibylle Loibl is head of the German Breast Group.

Prof. Dr. Loibl has gained international recognition for her research into neoadjuvant breast cancer therapy, breast cancer during pregnancy and breast cancer in young women. She was responsible for establishing the Translational Research Department within the German Breast Group and has headed numerous research projects. In addition, Prof. Dr. Loibl has been involved in conducting and managing a significant number of national and international clinical trials. In 2014, she was appointed to the Executive Board of the Breast International Group (BIG) and also sits on several international steering committees, translational research committees and independent data monitoring committees.

Prof. Dr. Loibl gained a doctorate at the Ruprecht Karl University of Heidelberg and trained as a consultant in gynaecology and obstetrics at the women’s clinics of the university hospitals in Heidelberg and Frankfurt am Main. She devotes most of her time to clinical research within the German Breast Group and clinical work at the Centrum für Hämatologie und Onkologie Bethanien, Frankfurt.

Prof. Dr. Loibl is author of more than 350 original and peer review articles, and co-author of more than 500 scientific papers cited by Medline; she has also written numerous books and book contributions. She is an active member of many important national and international organisations, such as ASCO, ESMO, EORTC-TRAFO, ESGO, DKG and the AGO Kommission Mamma and S3 Letilinienkommission to develop the breast cancer guidelines.